Items where authors include "Helliwell, P."

Article

McHugh, N., Tillett, W., Helliwell, P. orcid.org/0000-0002-4155-9105 et al. (7 more authors) (2024) Enhanced surveillance for the detection of psoriatic arthritis in a UK primary care psoriasis population: results from the TUDOR trial. Rheumatology. keae374. ISSN 1462-0324

Hen, O., Di Matteo, A., Dubash, S.R. et al. (7 more authors) (2024) High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort. RMD Open, 10 (2). e003841. ISSN 2056-5933

De Lorenzis, E. orcid.org/0000-0001-9819-105X, Kakkar, V., Di Donato, S. et al. (13 more authors) (2024) Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets. RMD Open, 10 (1). e003216. ISSN 2056-5933

Coyle, C., Watson, L., Whately-Smith, C. et al. (28 more authors) (2024) How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology. kead679. ISSN 1462-0324

Hailey, L., Bundy, C., Burstow, H. et al. (13 more authors) (2023) The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. Rheumatology, 62 (8). pp. 2716-2723. ISSN 1462-0324

Mease, P. orcid.org/0000-0002-6620-0457, Helliwell, P. orcid.org/0000-0002-4155-9105, Silwinska‐Stanczyk, P. et al. (12 more authors) (2023) Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis & Rheumatology, 75 (8). pp. 1370-1380. ISSN 2326-5191

Hailey, L. orcid.org/0000-0001-5769-8663, Bundy, C., Burstow, H. et al. (13 more authors) (2022) The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. Rheumatology, 62 (8). pp. 2716-2723. ISSN 1462-0324

Madan, J., Ades, T., Barton, P. et al. (9 more authors) (2015) Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy, 2 (2). pp. 113-125. ISSN 2198-6576

Gilworth, G., Emery, P., Barkham, N. et al. (3 more authors) (2009) Reducing work disability in Ankylosing Spondylitis -development of a work instability scale for AS. BMC Musculoskeletal Disorders , 10. ISSN 1471-2474

Firth, J., Hale, C., Helliwell, P. et al. (2 more authors) (2008) The prevalence of foot ulceration in patients with rheumatoid arthritis. Arthritis Care & Research, 59 (2). pp. 200-205.

Conference or Workshop Item

Winter, E., Dekkers, O., Andreasen, C. et al. (37 more authors) (2024) 2024 Clinical Practice Guideline for the Diagnosis and Treatment of Chronic Nonbacterial Osteitis (CNO) in Adults. In: 2024 Annual Meeting of the American Society for Bone and Mineral Research, 27-30 Sep 2024, Toronto, Canada.

Torgutalp, M., Azevedo, V., Baraliakos, X. et al. (39 more authors) (2024) Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS). In: ACR Convergence 2024, 14-19 Nov 2024, Washington, D. C..

Tillett, W.R., Coates, L., Vis, M. et al. (7 more authors) (2023) Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment. In: ACR Convergence 2023, 10-15 Nov 2023, San Diego, CA.

Crowley, A., Siegel, L., Wickersham, P. et al. (6 more authors) (2023) The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study. In: ACR Convergence 2023, 10-15 Nov 2023, San Diego, CA.

Tillett, W., Coates, L., Vis, M. et al. (7 more authors) (2023) POS1535 Early improvement in 3VAS/4VAS predicts reduced rates of radiographic change in bio-naive active psoriatic arthritis patients receiving Guselkumab treatment. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

Watson, L., Coyle, C., Brooke, M. et al. (25 more authors) (2023) Current prescribing practices in psoriatic arthritis - comparison between the UK and Europe. In: British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester - Hybrid.

McGonagle, D., Haaland, D., Helliwell, P. orcid.org/0000-0002-4155-9105 et al. (6 more authors) (2023) Improvement in Key PsA Core Domains With Guselkumab Treatment in an Enriched Population of ACR20 Non-responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, PA.

Proceedings Paper

Macleod, T., Dubash, S., Hyde, I. et al. (9 more authors) (2024) P51 Plaque psoriasis patients with psoriatic arthritis demonstrate a reduced regulatory capacity for neutrophil elastase compared with plaque psoriasis patients without arthritis. In: British Journal of Dermatology. 10th International Congress, Psoriasis: From Gene to Clinic, 05-07 Dec 2024, London, UK. Oxford University Press (OUP) , iii40.

Campbell, F., Harrison, S., Golenya, R. et al. (10 more authors) (2024) O12 Community Psoriasis: Phenotype and Comorbidity Assessment (COPPACA): an observational study of the prevalence, phenotype and health burden of psoriasis in the community. In: British Journal of Dermatology. 104th Annual Meeting of the British Association of Dermatologists, 02-04 Jul 2024, Manchester, UK. Oxford University Press , i7-i8.

Helliwell, P., Coates, L., Ransom, M. orcid.org/0000-0003-4359-8287 et al. (5 more authors) (2023) AB1147 The Comparative Performance of Three Screening Questionnaires for Psoriatic Arthritis in a Primary Care Surveillance Program. In: Annals of the Rheumatic Diseases. EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 1803-1804.

Mchugh, N., Bojke, L., Coates, L. et al. (7 more authors) (2023) OP0271 Incidence of Psoriatic Arthritis and Prevalence of Undiagnosed Cases in a UK Primary Care Population Followed Prospectively For 2 Years - Results from the TUDOR Randomized Clinical Trial. In: Annals of the Rheumatic Diseases. EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. BMJ Publishing Group , pp. 178-179.

Brown, S., Coates, L., Collier, H. et al. (6 more authors) (2023) POS0224 Enhanced Surveillance for the Detection of Psoriatic Arthritis in a UK Primary Care Psoriasis Population Versus Usual Care: Results at 24 Months from the the Total Burden of Psoriasis (TUDOR) Randomised Control Trial. In: Annals of the Rheumatic Diseases. EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy. Suppl 1, 82 . BMJ Publishing Group , pp. 339-340.

Coyle, C., Watson, L., Brooke, M. et al. (25 more authors) (2023) P174 Psoriatic arthritis patients in the UK have a lower quality of life than patients in mainland Europe - an analysis from the ASSIST study. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

Watson, L.L., Coyle, C., Brooke, M. et al. (25 more authors) (2023) P179 Shared decision-making in psoriatic arthritis consultations. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2022) 1017: Minimal Important Difference (MID), Minimal Detectable Change (MDC),and Disease Activity Thresholds for Two Novel Composite Instruments(3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of ThreePhase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2013-2015.

Coyle, C., Whately-Smith, C., Brooke, M. et al. (24 more authors) (2022) 1028: How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA? In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2040-2042.

Tillett, W., Coates, L., Kishimoto, M. et al. (4 more authors) (2022) 1268: Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2488-2490.

Yazji, S., Helliwell, P., Balanescu, A. et al. (13 more authors) (2022) 1496: Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met? In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2954-2957.

McGonagle, D., Haaland, D., Helliwell, P. et al. (6 more authors) (2022) 2113: Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. , pp. 4182-4184.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) 2127: Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4214-4216.

Tillett, W., Coates, L., Sharaf, M. et al. (7 more authors) (2022) 2142: Strong Correlation Between Short- vs Long-form Composite Measures ofPsoriatic Arthritis Disease Activity in a TNFi-IR Population Treated withGuselkumab: Data from the Phase 3b COSMOS Trial. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4248-4251.

Gladman, D.D., Mease, P.J., Bird, P. et al. (13 more authors) (2022) AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 1574-1575.

Tillett, W., Coates, L., Kishimoto, M. et al. (4 more authors) (2022) AB0904 Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 1580-1581.

Mulder, M.L.M., Vriezekolk, J.E., Van Hal, T. et al. (7 more authors) (2022) POS0078 Comparing Methotrexate Monotherapy With Methotrexate Plus Leflunomide Combination Therapy In Psoriatic Arthritis: A Randomised, Placebo-Controlled, Double-Blind Clinical Trial (Complete-PsA). In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , p. 259.

De Lorenzis, E., Kakkar, V., Ross, R. et al. (11 more authors) (2022) POS0876 Serum Interferon Score Predicts Severity Of Patient Reported Hand Disability In Systemic Sclerosis. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 733-734.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) POS1017 Guselkumab Provides Continued Improvement In Key Domains Of Psoriatic Arthritis Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 818-819.

Mease, P.J., Helliwell, P., Gladman, D.D. et al. (10 more authors) (2022) POS1037 Effect Of Guselkumab, A Selective Il-23p19 Inhibitor, On Axial-Related Endpoints In Patients With Active Psa: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 832-833.

Tillett, W., Coates, L., Neuhold, M. et al. (6 more authors) (2022) POS1043 Strong Correlation Between Short- Vs Long-Form Composite Measures Of Psoriatic Arthritis Disease Activity In A TNFi-IR Population Treated With Guselkumab: Data From The Phase 3b Cosmos Trial. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 838-839.

Preprint

Dand, N. orcid.org/0000-0002-1805-6278, Stuart, P.E., Bowes, J. et al. (82 more authors) (2023) GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. [Preprint]